JPMorgan views the Department of Veterans Affairs awarding TG Therapeutics an anti-CD20 antibody contract for Briumvi as an “unequivocal win for TGTX on two fronts.” The first being Briumvi securing a durable revenue stream and the second being the benefit to brand awareness as the preferred agent by a large institution, the analyst tells investors in a research note. The firm anticipates a near-term sentiment boost to the shares. However, with the Street “narrowly focusing on forward quarter performance,” it may take the setup of Q1 beat and/or raise to fiscal 2204 guidance for TG shares to resume an upward momentum, says JPMorgan. It has an Overweight rating on the shares with a $25 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
- TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
- TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
- TG Therapeutics presents data from ULTIMATE I & II, ENHANCE trials